Skip to main content
Journal cover image

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

Publication ,  Journal Article
Schiller, GJ; Lipe, BC; Bahlis, NJ; Tuchman, SA; Bensinger, WI; Sutherland, HJ; Lentzsch, S; Baljevic, M; White, D; Kotb, R; Chen, CI ...
Published in: Clin Lymphoma Myeloma Leuk
September 2023

BACKGROUND: The increasing use of anti-CD38 monoclonal antibodies (αCD38 mAbs) for newly diagnosed or early relapsed multiple myeloma (MM), especially in non-transplant eligible patients, may lead to more patients developing αCD38 mAb-refractory disease earlier in the treatment course with fewer treatment options. PATIENTS AND METHODS: We analyzed the efficacy and safety of selinexor-based triplets (selinexor+dexamethasone [Sd] plus pomalidomide [SPd, n = 23], bortezomib [SVd, n = 16] or carfilzomib (SKd, n = 23]) in a subset of STOMP (NCT02343042) and BOSTON (NCT03110562) study patients treated previously with αCD38 mAbs. RESULTS: Sixty-two patients (median 4 prior therapies, range 1 to 11, 90.3% refractory to αCD38 mAb) were included. Overall response rates (ORR) in the SPd, SVd and SKd cohorts were 52.2%, 56.3%, and 65.2%, respectively. Overall response rate was 47.4% among patients who had MM refractory to the third drug reintroduced in the Sd-based triplet. Median progression-free survival in the SPd, SVd, and SKd cohorts was 8.7, 6.7, and 15.0 months, respectively, and median overall survival was 9.6, 16.9, and 33.0 months, respectively. Median time to discontinuation in the SPd, SVd, and SKd cohorts was 4.4, 5.9, and 10.6 months, respectively. The most common hematological adverse events were thrombocytopenia, anemia, and neutropenia. Nausea, fatigue, and diarrhea were primarily grade 1/2. Adverse events were generally manageable with standard supportive care and dose modifications. CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Lymphoma Myeloma Leuk

DOI

EISSN

2152-2669

Publication Date

September 2023

Volume

23

Issue

9

Start / End Page

e286 / e296.e4

Location

United States

Related Subject Headings

  • Multiple Myeloma
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents
  • Antibodies, Monoclonal
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schiller, G. J., Lipe, B. C., Bahlis, N. J., Tuchman, S. A., Bensinger, W. I., Sutherland, H. J., … Gasparetto, C. (2023). Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. Clin Lymphoma Myeloma Leuk, 23(9), e286-e296.e4. https://doi.org/10.1016/j.clml.2023.06.001
Schiller, Gary J., Brea C. Lipe, Nizar J. Bahlis, Sascha A. Tuchman, William I. Bensinger, Heather J. Sutherland, Suzanne Lentzsch, et al. “Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.Clin Lymphoma Myeloma Leuk 23, no. 9 (September 2023): e286-e296.e4. https://doi.org/10.1016/j.clml.2023.06.001.
Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, et al. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e286-e296.e4.
Schiller, Gary J., et al. “Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.Clin Lymphoma Myeloma Leuk, vol. 23, no. 9, Sept. 2023, pp. e286-e296.e4. Pubmed, doi:10.1016/j.clml.2023.06.001.
Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, Lentzsch S, Baljevic M, White D, Kotb R, Chen CI, Rossi A, Biran N, LeBlanc R, Grosicki S, Martelli M, Gunsilius E, Špička I, Stevens DA, Facon T, Mesa MG, Zhang C, Van Domelen DR, Bentur OS, Gasparetto C. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e286-e296.e4.
Journal cover image

Published In

Clin Lymphoma Myeloma Leuk

DOI

EISSN

2152-2669

Publication Date

September 2023

Volume

23

Issue

9

Start / End Page

e286 / e296.e4

Location

United States

Related Subject Headings

  • Multiple Myeloma
  • Humans
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents
  • Antibodies, Monoclonal
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences